Application of cytokines in the treatment of breast cancer
DOI:
https://doi.org/10.54097/fkrca760Keywords:
Breast cancer; Cytokines; Therapy Interferon.Abstract
Breast cancer is one of the most common cancers in women globally. Breast cancer is still a major public health issue despite great advancements in diagnosis and treatment. In 2020, there will be about 2.3 million new cases of breast cancer, including about 600,000 deaths. In China, breast cancer is the most common cancer among women aged 15-44, and its mortality rate is on the rise. In recent years, researchers have focused on using cytokines as a potential therapy for breast cancer. Small proteins known as cytokines are essential in the immune system's response to cancer cells. This article discusses the current state of research on using cytokines to treat breast cancer. Specifically, it explores four methods of cytokine therapy: interferon therapy, tumor necrosis factor therapy, interleukin therapy, and colony-stimulating factor therapy. The article also examines the experimental evidence supporting the use of these therapies in treating breast cancer. Overall, this research suggests that cytokine therapy may hold promise as a new approach to treating breast cancer.
Downloads
References
Pashayan, Nora et al. “Personalized early detection and prevention of breast cancer: ENVISION consensus statement.” Nature reviews. Clinical oncology vol. 17,11 (2020): 687-705.
Tan, Puay Hoon et al. “The 2019 World Health Organization classification of tumours of the breast.” Histopathology vol. 77,2 (2020): 181-185.
Sung, Hyuna et al. “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.” CA: a cancer journal for clinicians vol. 71,3 (2021): 209-249.
Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. Journal of the National Cancer Center. 2022;2(1):1–9.
Esquivel-Velázquez, Marcela et al. “The role of cytokines in breast cancer development and progression.” Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research vol. 35,1 (2015): 1-16.
Shahid, Saman et al. “Mutations of the human interferon alpha-2b (hIFNα-2b) gene in cancer patients receiving radiotherapy.” American journal of cancer research vol. 5,8 2455-66. 15 Jul. 2015
Liu, Yu et al. “Tumor necrosis factor α inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer.” Cell death & disease vol. 11,11 993. 19 Nov. 2020.
Leonard, Warren J, and Jian-Xin Lin. “Strategies to therapeutically modulate cytokine action.” Nature reviews. Drug discovery, 10.1038/s41573-023-00746-x. 4 Aug. 2023.
Ardestani, Shidrokh et al. “Membrane versus soluble isoforms of TNF-α exert opposing effects on tumor growth and survival of tumor-associated myeloid cells.” Cancer research vol. 73,13 (2013): 3938-50.
Liu, Jiacui et al. “Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody.” International journal of pharmaceutics vol. 624 (2022): 121969.
Gupta, Meenakshi et al. “Natural products and their derivatives as immune check point inhibitors: Targeting cytokine/chemokine signalling in cancer.” Seminars in cancer biology vol. 86,Pt 2 (2022): 214-232.
Liu, Li et al. “The role of granulocyte colony stimulating factor in breast cancer development: A review.” Molecular medicine reports vol. 21,5 (2020): 2019-2029.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
